Newly Activated Studies

These studies have recently activated.

More information can be found on CTSU.

NRG-GY035: A Randomized Phase III Trial of Carboplatin, Pacitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer
NRG-HN015: A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)
A232402CD: PAGODA: Randomized Trial of Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays
WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network (STOP-VTE)
WF-2501CD: Practical Delivery of Geriatric Assessment in Community Oncology Settings (PGA)

Research Base Meetings

SWOG Spring Meeting: April 30-May 2, 2026-San Francisco, CA

ECOG-ACRIN Spring Meeting: May 5-7, 2026- Baltimore, MD

Alliance Spring Meeting: May 13-15, 2026 - Chicago, IL

Monthly Coordinator Call

Affiliate Site Staff Meeting (Coordinator Call)

Monthly Coordinator Meeting

Thursday, January 29, 2026

The meeting will be held from

2:00PM - 3:00PM

on Microsoft Teams

If you did not receive a recurring Teams calendar invite for these meetings, please reach out to Jessica Michael, jmichael@gibbscc.org.

The link for the next call is below

Coordinator Call

Accruals, Biospecimens, & Special Entries

Under-Represented Populations

All About AYAs

CCDR Corner

LOTS of new CCDR protocols!!

Recently a plethora of new CCDR protocols have been activated. New studies include A232402CD: PAGODA, WF-2502CD: STOP-VTE, and WF-2501CD: PGA. Summaries (taken from the protocols and training slides) are provided below:

A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays

Unplanned chemotherapy delays are common during cancer treatment and can have significant consequences for patients
The most common cause of delay is cytopenias.
In current clinical practice with FOLFOX regimens there is substantial variation in dose modifications/delays for neutropenia and thrombocytopenia.
There is a lack of consensus regarding best practices for FOLFOX dose adjustments.
In response to this the investigators recently developed PAGODA (proactive graduated dose modification algorithm) for FOLFOX.
This trial aims to evaluate the effectiveness of the PAGODA dose modification algorithm in reducing unplanned treatment delays during FOLFOX based chemotherapy.

WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)

The purpose of the research study is to evaluate the consistent use of guidelines by surgeons for extended pharmacologic venous thromboembolism (VTE) prophylaxis (ePPx) for patients after major cancer surgery
Involves surgeons who perform abdominopelvic cancer surgeries and their APPs who assist with post-operative care
Each participating site will identify the surgeons/APPs who will be emailed a 10-minute survey to complete
11-25 of those who complete the survey will be asked to complete a 30-minute virtual interview

WF-2501CD: Practical Delivery of Geriatric Assessment in Community Oncology Settings (PGA)

All older adult cancer patients who are candidates for systemic therapy should receive a geriatric assessment, but some individuals or clinics may need extra supports to implement the process.
This study aims to engage clinical, community, and patient representatives to:
1) provide feedback on proposed implementation strategies and facilitators and barriers to PGA delivery,
2) engage three practice sites
3) refine outcome data collection from surveys and EHR data abstraction based on survey response rates and clinic feedback.

Interested? Contact Melyssa!

Diving In!

American Cancer Society's Cancer Statistics 2026 Report

On January 13th, the American Cancer Society (ACS) released the 2026 Cancer Statistics Report. This report is the gold standard of cancer surveillance research in the United States. It highlights cancer facts, incidence, and mortality rate trends for the current year. In addition, the organization is celebrating the 75th anniversary of ACS researchers analyzing and disseminating cancer data to inform cancer control and help improve public health.

Data in the report, published by Siegel et al. in CA: A Cancer Journal for Clinicians, reveal new findings. The five-year relative survival rate for all cancers combined reached 70% for people diagnosed during 2015 – 2021 in the United States. Notably, among people diagnosed with multiple myeloma, liver cancer, and lung cancer (the leading cause of cancer death), survival has improved compared to the mid-1990s. This improvement is largely due to early detection and better treatments. However, although cancer mortality rates have continued to decline, incidence has continued to increase for many common cancers, such as breast, prostate, liver, melanoma, and pancreas (Siegel et al., 2026). This emphasizes the need for more investment in cancer research, prevention, and survivorship.

Despite these advancements, researchers are concerned that the progress made with many decades of scientific research and investment to increase survival rates among cancer patients may be at risk due to proposed changes to federally supported research and health insurance, which are key factors in patients having access to life-saving cancer treatments.

For more information, follow the Cancer Statistics 2026 Report link below:

Cancer Statistics 2026 Report

Smiling Faces

Josiah Sightler has officially joined the Regulatory Team as a Research Intern! Josiah earned a BA in Public Health from the University of South Carolina and is currently pursuing an MBA in Healthcare Management at Charleston Southern University. Prior to this role, he played professional baseball for the Pittsburgh Pirates, bringing a strong discipline and teamwork mindset to his work. Welcome to the team, Josiah!